SCN2A and epilepsy: Further investigation into the differences between the two models has identified calcium/calmodulin protein kinase II (CaMKII) as a modulator of the Scn2aQ54 phenotype [74], suggesting the CaMKII pathway may serve as a therapeutic target for SCN2A-associated epilepsy.